

8 July 2025
ASX Release

Argent BioPharma Commences Supply of EU-GMP Cannabinoid API for Epilepsy Treatment at Leading EU Hospital after Successful Pilot Program

HIGHLIGHTS

- **Clinical API supply launched:** EU-GMP cannabinoid-based API now in neurologist-recommended use in the Pediatric clinic at University Medical Centre Ljubljana, Slovenia's largest hospital, following completion of a positive pilot program
- **Builds on existing EU CannEpi[®] market position and success:** Leverages Argent's proven track record commercialising **CannEpi[®]** in Europe, and with Ireland's MCAP, demonstrating clinical confidence in cannabinoid therapies for Refractory Epilepsy
- **Protocol-driven:** Prescriptions follow dosing guidelines co-developed under Argent BioPharma's Epilepsy Program Platform (EPP)
- **Regulatory leadership:** In close collaboration with Slovenia's **Ministry of Health (MoH) and Agency for medicinal products and medical devices (JAZMP)**, Argent provided technical data, GMP validation and clinical evidence that shaped the national framework permitting hospital compounding of cannabinoid formulations
- **EU Pharmacopoeia compliance:** API manufactured to EU Pharmacopoeia standards, supporting regulated magistral preparations for treatment-resistant epilepsy patients


Epilepsy-Focused Supply to Leading EU Hospital Underway

Argent BioPharma (ASX: RGT) (**the Company**) has commenced formal supply of EU-GMP cannabinoid-based active pharmaceutical ingredient (API) to the **University Medical Centre Ljubljana (UKC)**. Transitioning from a structured pilot to routine hospital use, the RGT supply of this cannabinoid-based API enables neurologists to dispense **recommended, protocol-aligned formulations** for patients with drug-resistant epilepsy. This represents a significant new clinical milestone for the Company and opens new potential commercial opportunities for API supply to EU hospitals.

This milestone is the culmination of a multi-year collaboration between Argent and the Slovenian **University Medical Centre**. The Company's pre-clinical data, GMP dossiers and clinical experience with **CannEpi[®]** now govern hospital-based compounding of cannabinoid therapies for neurological indications. The API is produced by **PHCANN International/NYSK Holdings**, one of Argent's EU-GMP Manufacturing partners.

RGT Epilepsy Program Platform (EPP) – Core Activities

The EPP rests on five pillars. **EU-GMP manufacturing** secures consistent, high-quality production of APIs and finished-dose products, with our EU-GMP partners PHCANN International/NYSK Holdings. **Clinical research** spans investigator-initiated and Company-sponsored trials in refractory epilepsy. **Regulatory engagement** is exemplified by Argent's hands-on work with the Slovenian MoH, MCAP listing in Ireland and orphan-drug-pathway initiatives elsewhere. **Physician education and protocol development** provide neurologists with compounding guidelines, dosing algorithms and real-world data capture. Finally, the **commercial roll-out** pillar leverages **CannEpi[®]**'s success—expanding EU distribution and hospital collaborations.



Building on CannEpi[®] Experience

Argent's expertise stems from **CannEpi[®]**, which has demonstrated clinical utility in Ireland and other European markets. Lessons learned in dosing, safety monitoring and supply logistics directly informed both the MoH pathway and the newly collaboration, accelerating physician uptake and regulatory alignment.

Strategic Significance

Formal supply at UKC Ljubljana validates Argent's capability to convert pilot projects into full hospital programmes and highlights its leadership in shaping cannabinoid regulations alongside national health authorities. The initiative strengthens the EPP pipeline and supports forthcoming EU and U.S. expansion milestones.

Roby Zomer, Chairman, Argent BioPharma: *"Launching full clinical supply in Slovenia is a testament to our team's regulatory expertise and our longstanding commitment to patients with refractory epilepsy. By partnering with the UKC and leading clinicians, we are setting a new standard for cannabinoid-based neuroimmune therapies across Europe."*

Dr. David Neubauer, Senior Consultant Neurologist, UKC Ljubljana: *"Integrating a GMP-certified cannabinoid formulation—supported by detailed protocols and framework co-developed with Argent BioPharma—gives us an evidence-based option for the most complex epilepsy cases. Early results were encouraging, and we have developed strategies for the use of the Cannabinoid formulation for treatment of the most resistant epilepsies and encephalopathies for children and adolescents."*

Science meets protocol. Precision meets care.

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its lead assets, **CannEpi[®]** and **Cimetra[®]**, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The company's proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. With integrated EU-GMP manufacturing, clinical-stage programs, and a unified Neuro-Immune Modulatory platform, Argent BioPharma is advancing a high-impact pipeline that excludes oncology and focuses on urgent unmet needs in CNS and systemic inflammation

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com

